Skip to content

Dual Guidance Structure for Evaluation of Patients With Unclear Diagnosis in Centers for Rare Diseases

Duale Lotsenstruktur Zur Abklärung Unklarer Diagnosen in Zentren für Seltene Erkrankungen

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03563677
Acronym
ZSE-DUO
Enrollment
1379
Registered
2018-06-20
Start date
2018-10-15
Completion date
2022-09-30
Last updated
2023-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Orphan Diseases, Rare Diseases

Keywords

psychosomatic, unclear diagnosis

Brief summary

In people suffering from a rare disease the diagnostic process and the confirmation of a final diagnosis is often ongoing for many years. Factors contributing to delayed diagnosis include the limited knowledge of health care professionals about rare diseases and their symptoms but also a psychiatric or psychosomatic (co-)morbidity obscuring the symptoms of the rare disease. The project ZSE-DUO will evaluate whether a combination of an expert in somatic medicine and a psychiatric/psychosomatic specialist will increase the rate of assured diagnoses in patients approaching a center of rare diseases (primary outcome), accelerate the process until a diagnosis is made, reduce the costs of diagnosing a patient, and lead to a higher satisfaction of patients and health care professionals. Furthermore, the project will evaluate whether the use of psychosomatic screening tools at registration of a patient in a center for rare diseases will help to guide the diagnostic process. Two cohorts of 682 patients each will be sequentially recruited over 9 plus 9 months: the Control group cohort (CG based on somatic expertise) and the Experimental group cohort (EG combined psychosomatic/somatic expertise Included will be persons from the age of at least 12 years presenting with symptoms and signs which are not explained by current diagnoses (as judged by the patient's primary care physician and a specialized physician at the center for rare diseases ZSE evaluating the medical records). Patients will be recruited from 11 German Centers for Rare Diseases associated with University hospitals in the cities of Aachen, Bochum, Frankfurt, Hannover, Magdeburg, Mainz, Münster, Regensburg, Tübingen, Ulm and Würzburg. Recruitment will be supported by a collaboration with the German patient organization representing many rare disease organizations ACHSE e.V. and a collaboration with the insurance companies Techniker Krankenkasse, IKK gesund plus and AOK Hessen who also provide data on costs of care. Data collection and analysis will be coordinated and performed by the Institute for Clinical Epidemiology and Biometry at the University of Würzburg, the Institute for Epidemiology, Social Medicine and Science of Health Care Systems in Hannover, and the Department of Medical Psychology in Hamburg. The project is funded by the Innovationsfond of the Federal Joint Committee in Germany.

Interventions

OTHERdual expert guidance structure

Two medical experts, one somatic specialist and one psychiatrist/psychosomatic specialist see all medical records and the patients together

Sponsors

Hannover Medical School
CollaboratorOTHER
University Hospital, Aachen
CollaboratorOTHER
Allianz Chronischer Seltener Erkrankungen ACHSE e.V.
CollaboratorUNKNOWN
Goethe University
CollaboratorOTHER
Universität Münster
CollaboratorOTHER
St. Josef Hospital Bochum
CollaboratorOTHER
Otto-von-Guericke University Magdeburg
CollaboratorOTHER
University Medical Center Mainz
CollaboratorOTHER
University Hospital Regensburg
CollaboratorOTHER
University Hospital Tuebingen
CollaboratorOTHER
University Hospital Ulm
CollaboratorOTHER
IKK gesund plus
CollaboratorUNKNOWN
Techniker Krankenkasse
CollaboratorOTHER
University of Wuerzburg
CollaboratorOTHER
Universitätsklinikum Hamburg-Eppendorf
CollaboratorOTHER
AOK Hessen
CollaboratorINDUSTRY
LWL-Universitätsklinikum der Ruhr-Universität Bochum
CollaboratorUNKNOWN
Wuerzburg University Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

Recruitment of 682 patients into control group during first 12 months of the project and, thereafter, recruitment of 682 patients during subsequent 12 months

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* first contact with the Center for Rare Diseases for unclear diagnosis * suspicion of a rare disease but no established diagnosis * attending the Center for Rare Diseases as an outpatient * written informed consent

Exclusion criteria

* age \<12 years * incomplete medical records including summary letters, imaging studies, blood tests etc. * pre-diagnosed disease(s) explaining all symptoms

Design outcomes

Primary

MeasureTime frameDescription
Diagnoses made12 months after signing the consent formThe number of diagnoses explaining the symptomatology of the patient made during the evaluation process

Secondary

MeasureTime frameDescription
Patient satisfaction with diagnostic process using ZUF-812 months after signing the consent formThe patients' satisfaction with the diagnostic process is assessed in the total sample with the questionnaire ZUF-8 (Fragebogen zur Patientenzufriedenheit - patient satisfaction questionnaire) and in a randomly selected subsample of about 40 patients by structured telephone interviews.
Costs of the diagnostic processup to 12 months after signing the consent fromestimated costs from first contact with the center for rare diseases until a diagnosis explaining the symptoms has been established
Time to diagnosis12 months after signing the consent formThe time it takes to make a diagnosis
Physician satisfaction with new form of care using new questionnaire30 months after the project start (end of the intervention period)The satisfaction of physicians working in the Centers fro Rare Diseases with the new form of care compared to standard care will be assessed by a newly developed questionnaire administered to all physicians involved in patient care in the 11 centers. For the development of the questionnaire, 3 focus groups of 10 physicians each will be questioned.
Value of screening instruments for psychiatric-psychosomatic (co-)morbidities30 months after the project start (end of intervention period)Performance of screening tools to identify patients with psychiatric-psychosomatic comorbidities against the judgement of a psychiatrist/psychosomatic expert seeing the patient (intervention group only)
Patients' quality of life using EQ-5D and SF12 (or KIDSCREEN-10 for children)12 months after signing the consent fromChange in the patients' quality of life as assessed with the Quality of life questionnaires EQ-5D from the EuroQoL Group in all patients and Short Form 12 (SF-12) in patients 16 years and older. In patients younger than 16 years, the health-related quality of life questionnaire for children and adolescents KIDSCREEN-10 is used.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026